Block listing Interim Review
RNS Number : 2594A
Vernalis PLC
29 March 2017



VERNALIS PLC (the "Company")


29 March 2017


Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:


Name of applicant:

Vernalis plc

Name of scheme(s):

2007 Long Term Incentive Scheme ("LTIP") and 2016 Executive Incentive Plan ("EIP")

Period of return (from / to):

From: 29/Sept/2016

To: 29/March/2017

Balance of unallotted securities under scheme(s) from previous return:

Total of 401,056 Ordinary 1p Shares under LTIP

Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for):

Total of 499,612 Ordinary 1p Shares, split:

· Under LTIP   =   199,026 Ordinary 1p Shares

· Under EIP     =   300,586 Ordinary 1p Shares

As applied for in the below paragraph.

Less: Number of securities issued/allotted under scheme(s) during period:

Total of 163,876 Ordinary 1p Shares under LTIP

Less: Number of securities forfeited under scheme(s) during period:

Total of 8,001 Ordinary 1p Shares under LTIP

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

Total of 728,791 Ordinary 1p Shares, split:

· Under LTIP   =   428,205 Ordinary 1p Shares

· Under EIP     =   300,586 Ordinary 1p Shares

Number and class of securities originally admitted and the date of admission (including any additions):

No. of Ordinary 1p Shares

Date on which Shares were Admitted to Trading


6 November 2013, plus


12 May 2014, plus


12 May 2015, plus


30 September 2015


1 April 2016


31 March 2017




Vernalis plc announces that application has been made to the London Stock Exchange for the admission of 499,612 Ordinary Shares of 1 pence each (the "Ordinary Shares") in the Company under the Company's existing block listing scheme. These Ordinary Shares will be available to satisfy future exercises of options over Ordinary Shares under the Company's employee share schemes being: the LTIP; and the EIP. It is expected that admission will become effective on 31 March 2017.  When issued, these shares will rank pari passu with the existing Ordinary Shares.


-- ends -





Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer


Canaccord Genuity Limited (Nominated Adviser and Joint Broker):

+44 (0) 20 7523 8000

Henry Fitzgerald-O'Connor

Emma Gabriel


Shore Capital (Joint Broker):

+44 (0) 20 7408 4090

Bidhi Bhoma

Toby Gibbs


FTI Consulting:

+44 (0) 20 3727 1000

Ben Atwell

Simon Conway

Stephanie Cuthbert



Notes to Editors


About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra® XR targeting the US prescription cough-cold market; Moxatag®, a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focused on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris. 


For further information about Vernalis, please visit 


This information is provided by RNS
The company news service from the London Stock Exchange